ARCHIVES

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008

NCI Awards $6.7 Million For Breast Cancer Research.

September 8, 2000

Endostatin Enters Phase II Trial For Neuroendocrine Tumors.

December 14, 2001

CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup

January 27, 2012

In Brief: Urologist Appointed To NCAB; Stovall Named To US Pharmacopeia Oncology Advisory Panel

September 8, 1995

New Approach To Replacing Immune Cells Shrinks Tumors

September 27, 2002